title: The myeloproliferative disorders. An historical appraisal and personal experiences.
abstract: According to strict morphological, biochemical and cytogenetic criteria Philadelphia chromosome positive essential thrombocythemia and chronic granulocytic leukemia constitute a separate malignant and individual disease entity, whereas Philadelphia chromosome negative essential thrombocythemia, polycythemia vera and agnogenic or megakaryocytic myeloid metaplasia form a chronic proliferation of three hematopoietic cell lines. Histopathology from bone marrow biopsies permits the characterization and diagnostic differention of the various myeloproliferative disorders and appears to be a main and specific diagostic criterion for polycythemia vera and essential thrombocythemia. Hemorrhagic thrombocythemia is a clinical syndrome of recurrent spontaneous mucocutaneous and secondary hemorrhages often preceded by thromboses, extremely high platelet counts, pseudohyperkalemia, increased bone marrow cellularity and frequently splenomegaly. The diagnostic criteria of essential thrombocythemia with paradoxical occurrence of thrombotic events and hemorrhagic manifestations are a platelet count in excess of 1000 x 10(9)/L and increased bone marrow cellularity in the majority of the cases. Erythromelalgia and other microcirculatory ischemic or thrombotic events or accidents in essential thrombocythemia and polycythemia vera already occur at platelet counts in excess of the upper limit of normal. First line treatment options in essential thrombocythemia and polycythemia vera are control of platelet function with low-dose aspirin and reductive control of platelet count and erythrocytes by bloodletting, interferon and busulfan or hydroxyurea monochemotherapy.
authors.affiliation: Department of Hematology, University Hospital Dijkzigt, Erasmus University Medical School Rotterdam, The Netherlands.
authors.forename: J J
authors.initials: JJ
authors.lastname: Michiels
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D002455:Cell Division; D003131:Combined Modality Therapy; D005260:Female; D049673:History, 20th Century; D006801:Humans; D008297:Male; D009196:Myeloproliferative Disorders / Q000145:classification / Q000175:diagnosis / Q000266:history / Q000473:pathology; D010292:Paresthesia / Q000209:etiology; D011087:Polycythemia Vera / Q000150:complications / Q000188:drug therapy / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis / Q000473:pathology; D013927:Thrombosis / Q000209:etiology; D014652:Vascular Diseases / Q000209:etiology